Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Table 6 Evaluation of factors affecting time to resolution^a

Effect (numerator)	Odds ratio	95% CI	P value
Univariate analysis^b
BMI (≥ 25 kg/m²)	1.52	–	0.072
C1-INH rescue medication (yes)	0.66	–	0.097
Affected site: skin (yes)	0.74	–	0.118
Type of administration (HCP)	1.49	–	0.133
Time to first injection (≥ 1 h)	0.78	–	0.142
Country			0.019^c
Multivariate analysis^d
BMI (≥ 25 kg/m²)	4.46	2.24–8.89	< 0.0001
C1-INH rescue medication (yes)	0.31	0.19–0.50	< 0.0001
Affected site: skin (yes)	0.65	0.43–1.00	0.049

BMI body mass index; C1-INH C1-inhibitor; CI confidence interval; HCP health care provider
^aModel of probability that time to resolution < 5 h
^bOnly effects with P < 0.2 are shown. Complete results are presented in Additional file 1: Table S7
^cOverall effect of country on time to resolution
^dOnly significant effects are shown. Complete results excluding the two reinjection outliers are presented in Additional file 1: Table S8

ISSN: 2045-7022